HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Y Okada Selected Research

YM 158

5/2000In vivo pharmacologic profile of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors.
4/2000Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Y Okada Research Topics

Disease

36Neoplasms (Cancer)
02/2012 - 01/2000
15Carcinoma (Carcinomatosis)
04/2016 - 01/2000
10Inflammation (Inflammations)
11/2016 - 10/2000
10Neoplasm Metastasis (Metastasis)
11/2011 - 01/2000
9Hemorrhage
08/2019 - 04/2000
8Infections
11/2018 - 02/2000
7Glioma (Gliomas)
08/2001 - 01/2000
6Ischemia
01/2018 - 11/2000
6Brain Death (Brain Dead)
04/2015 - 11/2000
6Rheumatoid Arthritis
11/2014 - 05/2000
6Wounds and Injuries (Trauma)
10/2014 - 11/2000
5Carcinogenesis
01/2017 - 03/2000
5Pathologic Constriction (Stenosis)
01/2016 - 04/2001
5Thrombosis (Thrombus)
01/2016 - 04/2000
5Glioblastoma (Glioblastoma Multiforme)
03/2001 - 01/2000
4Leukemia
12/2018 - 09/2013
4Hypoxia (Hypoxemia)
01/2018 - 11/2000
4Bronchiolitis Obliterans
09/2017 - 11/2000
4Melanoma (Melanoma, Malignant)
11/2011 - 10/2000
4Hematoma
07/2011 - 12/2000
4Ischemic Stroke
02/2010 - 10/2005
4Osteoarthritis
06/2009 - 06/2000
4Adenocarcinoma
06/2005 - 01/2000
4Heart Arrest (Cardiac Arrest)
10/2001 - 11/2000
4Burns
09/2001 - 01/2001
3Familial Primary Pulmonary Hypertension
04/2018 - 11/2000
3Body Weight (Weight, Body)
01/2018 - 02/2000
3Hepatocellular Carcinoma (Hepatoma)
01/2017 - 03/2000
3Colitis
12/2013 - 10/2000
3Insulin Resistance
05/2013 - 02/2000
3Stroke (Strokes)
08/2010 - 10/2005
3Necrosis
01/2007 - 04/2003
3Lymphatic Metastasis
01/2007 - 01/2000
3Adenoma (Adenomas)
04/2004 - 06/2001
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2001 - 11/2000
3Testicular Neoplasms (Testicular Cancer)
05/2001 - 02/2000
3Cataract (Cataracts)
12/2000 - 03/2000
3Urinary Bladder Neoplasms (Bladder Cancer)
12/2000 - 02/2000
2Primary Myelofibrosis (Myelosclerosis)
12/2018 - 12/2017
2Lupus Nephritis
02/2018 - 02/2013
2Reperfusion Injury
01/2018 - 10/2001
2Hypertension (High Blood Pressure)
05/2013 - 02/2000
2Cerebral Hemorrhage
08/2012 - 10/2005
2Lung Neoplasms (Lung Cancer)
07/2012 - 12/2009
2Pulmonary Edema
07/2012 - 01/2001
2Lymphoma (Lymphomas)
02/2012 - 10/2001

Drug/Important Bio-Agent (IBA)

15Proteins (Proteins, Gene)FDA Link
12/2018 - 01/2000
12Matrix Metalloproteinases (MMPs)IBA
02/2012 - 01/2000
11CytokinesIBA
01/2018 - 10/2000
10Messenger RNA (mRNA)IBA
10/2014 - 03/2000
8Pharmaceutical PreparationsIBA
08/2019 - 04/2000
7EnzymesIBA
02/2012 - 01/2000
7Metalloproteases (Metalloproteinases)IBA
01/2007 - 01/2000
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2018 - 10/2001
5InterleukinsIBA
06/2006 - 10/2000
5Matrix Metalloproteinase 14 (MT1-MMP)IBA
03/2001 - 01/2000
4Capsules (Microcapsules)IBA
10/2011 - 04/2000
4RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
12/2009 - 03/2000
4Hormones (Hormone)IBA
11/2004 - 02/2000
4Matrix Metalloproteinase 2 (Gelatinase A)IBA
11/2001 - 07/2000
4Enzyme Precursors (Zymogens)IBA
11/2001 - 01/2000
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2001 - 06/2000
4Tissue Inhibitor of Metalloproteinase-1IBA
03/2001 - 01/2000
4Tissue Inhibitor of Metalloproteinase-2IBA
03/2001 - 01/2000
4progelatinaseIBA
03/2001 - 01/2000
3Interleukin-6 (Interleukin 6)IBA
01/2018 - 04/2001
3LipidsIBA
01/2017 - 04/2000
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2016 - 03/2001
3FibrinolysinFDA Link
01/2015 - 10/2000
3Biomarkers (Surrogate Marker)IBA
02/2010 - 09/2005
3Insulin (Novolin)FDA Link
05/2008 - 02/2000
3Peptide Hydrolases (Proteases)FDA Link
01/2007 - 09/2000
3Interleukin-1alpha (Interleukin 1 alpha)IBA
06/2006 - 04/2001
3Indicators and Reagents (Reagents)IBA
06/2006 - 01/2001
3Cisplatin (Platino)FDA LinkGeneric
01/2006 - 12/2000
3AntigensIBA
10/2003 - 05/2000
3Complementary DNA (cDNA)IBA
04/2003 - 02/2000
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
11/2001 - 06/2000
3AntibodiesIBA
08/2001 - 03/2000
3Transforming Growth Factor beta (TGF-beta)IBA
03/2001 - 03/2000
3Glucose (Dextrose)FDA LinkGeneric
11/2000 - 02/2000
2Tacrolimus (Prograf)FDA LinkGeneric
02/2018 - 02/2013
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2018 - 03/2001
2salicylhydroxamic acid (SHAM)IBA
01/2018 - 01/2001
2PerforinIBA
09/2017 - 04/2006
2P-SelectinIBA
01/2016 - 10/2010
2Dextrans (Dextran)FDA Link
12/2013 - 05/2006
2SodiumIBA
12/2013 - 05/2006
2Therapeutic UsesIBA
06/2013 - 12/2009
2Brain Natriuretic Peptide (Natrecor)FDA Link
05/2013 - 02/2010
2AlkaliesIBA
02/2013 - 08/2006
2Anti-Bacterial Agents (Antibiotics)IBA
07/2012 - 05/2001

Therapy/Procedure

12Therapeutics
02/2018 - 01/2000
9Lung Transplantation
11/2018 - 11/2002
6Drug Therapy (Chemotherapy)
06/2010 - 02/2000
4Resuscitation
10/2001 - 05/2000
3Liver Transplantation
11/2016 - 11/2000
3Sternotomy
01/2001 - 11/2000
2Cardiopulmonary Bypass (Heart-Lung Bypass)
04/2016 - 01/2001
2Renal Dialysis (Hemodialysis)
07/2012 - 12/2000